Shah Capital boosts Novavax stake, escalates activism
Shah Capital files Amendment No. 6 to its Schedule 13D on Novavax, Inc., updating its ownership and activist intentions.
Rhea-AI Filing Summary
Shah Capital files Amendment No. 6 to its Schedule 13D on Novavax, Inc., updating its ownership and activist intentions. The filing shows Shah Capital Management and related entities beneficially owning up to 14,845,097 shares of Novavax common stock, or 9.11% of the company, based on shares outstanding as of February 16, 2026.
Most shares are held through Shah Capital Opportunity Fund LP, which directly owns 14,000,000 shares, while Himanshu H. Shah personally owns 125,359 shares. The amendment discloses that all shares, other than Mr. Shah’s personal holdings, were acquired using investment capital through open-market purchases.
The filing also notes an April 8, 2026 open letter from Shah Capital to Novavax’s board stating its intention to vote against board nominees and executive compensation. The letter cites concerns such as value destruction, a pessimistic 2026 revenue forecast, low institutional credibility, cost discipline and profitability, and governance changes.
Positive
- None.
Negative
- None.
Insights
Shah Capital discloses a ~9% Novavax stake and escalates activism with a critical board letter.
Shah Capital Management, Shah Capital Opportunity Fund LP, and Himanshu H. Shah report beneficial ownership of up to 14,845,097 Novavax shares, or 9.11% of the common stock, based on the stated outstanding share count. This level approaches the 10% threshold often associated with significant influence.
The amendment highlights an April 8, 2026 open letter to Novavax’s board declaring an intention to vote against board nominees and executive compensation. The letter cites concerns including value destruction, a pessimistic 2026 revenue forecast, institutional credibility, cost discipline, and governance. While no new share purchases are reported in the past 60 days, the combination of a large stake and stated voting intentions suggests elevated governance pressure, and future company responses or proxy materials may provide additional context.
Key Figures
Key Terms
Schedule 13D regulatory
beneficially owns financial
Sole Voting Power financial
open market purchases financial
Shah Capital Open Letter financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Novavax (NVAX) does Shah Capital report in this Schedule 13D/A?
Who are the reporting persons in the Novavax (NVAX) Schedule 13D/A Amendment No. 6?
What activist actions does Shah Capital signal toward Novavax (NVAX) in this amendment?
How much of Novavax (NVAX) does Shah Capital Opportunity Fund LP alone beneficially own?
AI-generated analysis. How Rhea-AI works. Not financial advice.